Immunogenicity and Protective Efficacy of Recombinant Fusion Proteins Containing Spike Protein of Infectious Bronchitis Virus and Hemagglutinin of H3N2 Influenza Virus in Chickens

Overview

Journal Virus Res

Specialty Microbiology

Date 2016 Aug 8

PMID 27497621

Citations 3

Authors

Lijuan Yin

Yuyao Zeng

Wei Wang

Ying Wei

Chunyi Xue

Yongchang Cao

Affiliations

Soon will be listed here.

Abstract

Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens and vaccination is the main method for disease control. The S1 protein, which contains several virus neutralization epitopes, is considered to be a target site of vaccine development. However, although protective immune responses could be induced by recombinant S1 protein, the protection rate in chickens was still low (<50%). Here, we generated fused S1 proteins with HA2 protein (rS1-HA2) or transmembrane domain and cytoplasmic tail (rS1-H3(TM)) from hemagglutinin of H3N2 influenza virus. After immunization, animals vaccinated with fusion proteins rS1-HA2 and rS1-H3(TM) demonstrated stronger robust humoral and cellular immune responses than that of rS1 and inactivated M41 vaccine. The protection rates of groups immunized with rS1-HA2 (87%) were significantly higher than the groups inoculated with rS1 (47%) and inactivated M41 vaccine (53%). And chickens injected with rS1-H3(TM) had similar level of protection (73%) comparing to chickens vaccinated with rS1 (47%) (P=0.07). Our data suggest that S1 protein fused to the HA2 or TM proteins from hemagglutinin of H3N2 influenza virus may provide a new strategy for high efficacy recombinant vaccine development against IBV.

Citing Articles

Construction and efficacy of a recombinant QX-like infectious bronchitis virus vaccine strain.

Lin L, Feng K, Shao G, Gong S, Liu T, Chen F Virus Genes. 2025; .

PMID: 40014292 DOI: 10.1007/s11262-025-02140-8.

Vaccine Candidate Delivering Infectious Bronchitis Virus S1 Protein to Induce Protection.

Liu K, Li Z, Li Q, Wang S, Curtiss 3rd R, Shi H Biomolecules. 2024; 14(1).

PMID: 38275762 PMC: 10813627. DOI: 10.3390/biom14010133.

A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin.

Hasan A, Paray B, Hussain A, Qadir F, Attar F, Aziz F J Biomol Struct Dyn. 2020; 39(8):3025-3033.

PMID: 32274964 PMC: 7189411. DOI: 10.1080/07391102.2020.1754293.

Protection against infectious bronchitis virus by spike ectodomain subunit vaccine.

Eldemery F, Joiner K, Toro H, van Santen V Vaccine. 2017; 35(43):5864-5871.

PMID: 28899630 PMC: 7111290. DOI: 10.1016/j.vaccine.2017.09.013.

References

Cavanagh D . Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 2003; 32(6):567-82. PMC: 7154303. DOI: 10.1080/03079450310001621198. View

Kam Y, Kien F, Roberts A, Cheung Y, Lamirande E, Vogel L . Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2006; 25(4):729-40. PMC: 7115629. DOI: 10.1016/j.vaccine.2006.08.011. View

Collisson E, Pei J, Dzielawa J, Seo S . Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev Comp Immunol. 2000; 24(2-3):187-200. DOI: 10.1016/s0145-305x(99)00072-5. View

Cook J, Jackwood M, Jones R . The long view: 40 years of infectious bronchitis research. Avian Pathol. 2012; 41(3):239-50. DOI: 10.1080/03079457.2012.680432. View

Doherty P, Topham D, Tripp R, Cardin R, Brooks J, Stevenson P . Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev. 1998; 159:105-17. DOI: 10.1111/j.1600-065x.1997.tb01010.x. View

Kotani T, Wada S, Tsukamoto Y, Kuwamura M, Yamate J, Sakuma S . Kinetics of lymphocytic subsets in chicken tracheal lesions infected with infectious bronchitis virus. J Vet Med Sci. 2000; 62(4):397-401. DOI: 10.1292/jvms.62.397. View

Raj G, Jones R . Infectious bronchitis virus: Immunopathogenesis of infection in the chicken. Avian Pathol. 2008; 26(4):677-706. PMC: 7154304. DOI: 10.1080/03079459708419246. View

Mckinley E, Jackwood M, Hilt D, Kissinger J, Robertson J, Lemke C . Attenuated live vaccine usage affects accurate measures of virus diversity and mutation rates in avian coronavirus infectious bronchitis virus. Virus Res. 2011; 158(1-2):225-34. PMC: 7114461. DOI: 10.1016/j.virusres.2011.04.006. View

Cavanagh D, Davis P, Pappin D, Binns M, Boursnell M, Brown T . Coronavirus IBV: partial amino terminal sequencing of spike polypeptide S2 identifies the sequence Arg-Arg-Phe-Arg-Arg at the cleavage site of the spike precursor propolypeptide of IBV strains Beaudette and M41. Virus Res. 1986; 4(2):133-43. PMC: 7133853. DOI: 10.1016/0168-1702(86)90037-7. View

10.

Ladman B, Pope C, Ziegler A, Swieczkowski T, Callahan C, Davison S . Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98. Avian Dis. 2002; 46(4):938-44. DOI: 10.1637/0005-2086(2002)046[0938:POCALA]2.0.CO;2. View

11.

Delmas B, Laude H . Assembly of coronavirus spike protein into trimers and its role in epitope expression. J Virol. 1990; 64(11):5367-75. PMC: 248586. DOI: 10.1128/JVI.64.11.5367-5375.1990. View

12.

Kant A, Koch G, van Roozelaar D, Kusters J, Poelwijk F, van der Zeijst B . Location of antigenic sites defined by neutralizing monoclonal antibodies on the S1 avian infectious bronchitis virus glycopolypeptide. J Gen Virol. 1992; 73 ( Pt 3):591-6. DOI: 10.1099/0022-1317-73-3-591. View

13.

Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M . A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006; 24(17):3624-31. PMC: 7115485. DOI: 10.1016/j.vaccine.2006.01.059. View

14.

Zhang J, Chen X, Tong T, Ye Y, Liao M, Fan H . BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens. Vaccine. 2013; 32(6):664-70. DOI: 10.1016/j.vaccine.2013.12.006. View

15.

Cavanagh D . Coronavirus IBV: structural characterization of the spike protein. J Gen Virol. 1983; 64 ( Pt 12):2577-83. DOI: 10.1099/0022-1317-64-12-2577. View

16.

Song C, Lee Y, Lee C, Sung H, Kim J, Mo I . Induction of protective immunity in chickens vaccinated with infectious bronchitis virus S1 glycoprotein expressed by a recombinant baculovirus. J Gen Virol. 1998; 79 ( Pt 4):719-23. DOI: 10.1099/0022-1317-79-4-719. View

17.

Liu Q, Liu K, Xue C, Zhou J, Li X, Luo D . Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice. Vaccine. 2014; 32(25):3041-9. PMC: 7115591. DOI: 10.1016/j.vaccine.2014.03.058. View

18.

Ignjatovic J, Galli L . The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens. Arch Virol. 1994; 138(1-2):117-34. PMC: 7087189. DOI: 10.1007/BF01310043. View

19.

Bijlenga G, Cook J, Gelb Jr J, de Wit J . Development and use of the H strain of avian infectious bronchitis virus from the Netherlands as a vaccine: a review. Avian Pathol. 2005; 33(6):550-7. PMC: 7154294. DOI: 10.1080/03079450400013154. View

20.

Koch G, Hartog L, Kant A, van Roozelaar D . Antigenic domains on the peplomer protein of avian infectious bronchitis virus: correlation with biological functions. J Gen Virol. 1990; 71 ( Pt 9):1929-35. DOI: 10.1099/0022-1317-71-9-1929. View